论文部分内容阅读
目的:研究子宫、卵巢特殊类型癌C-erbB-2的扩增以及与临床病理特征和患者预后的关系。方法:应用鉴别聚合酶链反应(DPCR)检测子宫、卵巢特殊型癌标本23例C-erbB-2癌基因的扩增。结果:23份中,16份(69.5%)含有扩增的C-erbB-2(2～8倍不等),其中子宫内膜透明细胞腺癌、子宫恶性苗勒管混合瘤及卵巢的子宫内膜样癌全部含有扩增的C-erbB-2;子宫乳头状浆液性癌、子宫内膜间质肉瘤、子宫内膜腺棘癌、腺鳞癌中则部分有扩增。组织学分化差、临床期别晚的患者有较高的C-erbB-2扩增率。术后随诊6～48个月,无瘤生存13例中,9例C-erbB-2扩增、占69.2%;带瘤生存及死于肿瘤的10例中,8例C-erbB-2扩增、占80%,但差异无显著性(P>0.05)。结论:同常见典型的子宫内膜腺癌一样,C-erbB-2在子宫、卵巢特殊型癌中亦有较高的扩增率。C-erbB-2扩增对预测此类肿瘤患者预后的价值,有待进一步研究。
OBJECTIVE: To study the amplification of C-erbB-2 in uterus and ovary, and its relationship with clinicopathological features and prognosis. Methods: The amplification of C-erbB-2 oncogene in 23 cases of uterus and ovary special type of cancer was detected by differential polymerase chain reaction (DPCR). Results: Of the 23 samples, 16 (69.5%) contained amplified C-erbB-2 (2-8 fold), including clear cell adenocarcinoma of the endometrium, Endometrioid carcinoma contains all of the amplified C-erbB-2; uterine papillary serous carcinoma, endometrial stromal sarcoma, endometrial adenocarcinoma, adenosquamous carcinoma is part of the amplification. Histologically poorly differentiated, late clinical patients with higher C-erbB-2 amplification rate. Of the 13 cases who were followed up for 6 to 48 months, 9 cases had C-erbB-2 amplification, accounting for 69.2%. Of the 10 cases with tumor-surviving and tumor-killing, 8 cases of C-erbB-2 Amplification, accounting for 80%, but no significant difference (P> 0.05). CONCLUSION: C-erbB-2, like the typical typical endometrial adenocarcinoma, has a high rate of amplification in uterine and ovarian special carcinomas. The value of C-erbB-2 amplification in predicting the prognosis of patients with such tumors needs further study.